<DOC>
	<DOCNO>NCT02564549</DOCNO>
	<brief_summary>Phase II non-inferiority randomize trial annual systematic biopsy versus mpMRI target biopsy men low risk prostate cancer active surveillance volume Gleason 's Score 6 , prior MRI image prostate .</brief_summary>
	<brief_title>MRI-Based Active Surveillance Avoid Risks Serial Biopsies Men With Low-Risk Prostate Ca</brief_title>
	<detailed_description>This unblinded , randomized trial TRUS biopsy-based active surveillance versus mpMRI-based active surveillance . Patients TRUS biopsy-based arm undergo annual systematic biopsy without MRI stag guidance . Patients mpMRI- base arm undergo annual mpMRI surveillance imaging , image-guided targeted biopsy indicate radiographic finding .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Prostate adenocarcinoma diagnose biopsy within 12 month prior study registration . Gleason score â‰¤ 6 PSA &lt; 10 ng/mL Completed documented history physical address inclusion/exclusion criterion . A diagnosis prostate adenocarcinoma one set prostate biopsy , separate calendar date . Previous MRI image prostate . Prior history pelvic radiotherapy . Prior history prostatectomy . Contraindication prostate mpMRI ( renal failure , hip prosthesis , pacemaker , etc ) . Contraindication prostate biopsy via transrectal transperineal approach ( include coagulopathy ) . Patients testosterone replacement therapy unwilling discontinue . Medical , psychological , social condition , opinion investigator , may increase patient 's risk limit patient 's adherence study requirement . Unable understand , unwilling complete inform consent process .</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>low risk prostate cancer</keyword>
</DOC>